Biomea Fusion Insiders Recover Some Losses, Which Stand At US$91k
Insiders who purchased US$156.0k worth of Biomea Fusion, Inc. (NASDAQ:BMEA) shares over the past year recouped some of their losses after price gained 13% last week. However, the purchase is proving to be a costly gamble, since losses made by insiders have totalled US$91k since the time of purchase.
Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
In the last twelve months, the biggest single purchase by an insider was when Independent Director Michael J. Hitchcock bought US$101k worth of shares at a price of US$10.06 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$2.87). Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.
Biomea Fusion insiders may have bought shares in the last year, but they didn't sell any. They paid about US$6.93 on average. This is nice to see since it implies that insiders might see value around current prices. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
View our latest analysis for Biomea Fusion
Biomea Fusion is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Biomea Fusion insiders own about US$13m worth of shares. That equates to 13% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
It doesn't really mean much that no insider has traded Biomea Fusion shares in the last quarter. On a brighter note, the transactions over the last year are encouraging. Insiders do have a stake in Biomea Fusion and their transactions don't cause us concern. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Biomea Fusion. Case in point: We've spotted 3 warning signs for Biomea Fusion you should be aware of, and 2 of them are a bit concerning.
But note: Biomea Fusion may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
27 minutes ago
- Forbes
Incoming 2026 Tesla Model S Triggers Hefty Price Cut On Outgoing Version
Tesla Motors Chairman and CEO Elon Musk (in driver's seat) and chief designer Franz von Holzhausen ... More (in passenger seat) drive the new Tesla Model S all-electric sedan as members of the media look on, at the car's unveiling in Hawthorne, California on March 26, 2009. Musk said the state-of-the-art, five-seat sedan will be the world's first mass-produced, highway-capable electric car. The car has an anticipated base price of 57,400 US dollars but will cost less than 50,000 after a federal tax credit of 7,500 dollars. AFP PHOTO / Robyn BECK (Photo credit should read ROBYN BECK/AFP via Getty Images) A new Tesla model almost always means an inventory fire sale on the older model. And that's what's happening to the Model S. The Model S has been around longer than any Tesla vehicle save the original Roadster. The Model S debuted in June 2012, got an update in 2016 and another in 2021. Now that version is being phased out to make room for the 2026 model. That means the previous Model S is getting the discount treatment. Price adjustments (discounts) range up to $7,620 for the Plaid Model S. Here are some highlights of the discounts on 'new' 2025 Model S on Tesla's inventory page. Model S All-Wheel Drive: $76,590 after $5,900 discount. A demo vehicle with 1,673 miles. Range: 312 miles. Model S All-Wheel Drive: $76,720 after $5,770 discount. Range: 410 miles. Model S Plaid: $90,030 after $6,460 discount. A demo vehicle with 1,242 miles. Range: 410 miles. Model S Plaid: $96,370 after $7,620 discount. Demo Vehicle with 111 miles. Range: 312 miles. The new 2026 Model S, by comparison, starts at $84,990. The good news for those looking at the older version is that the new Model S is not a radical makeover. It's a 'facelift' which means mostly subtle changes and, for the average consumer, it's hard to tell the difference cosmetically (though Tesla may claim otherwise). Differences are generally minor including updated wheels, a new paint option, and minor bumper tweaks.
Business Insider
2 hours ago
- Business Insider
Upcoming Stock Splits This Week (June 16 to June 20)
These are the upcoming stock splits for the week of June 16 to June 20, based on TipRanks' Stock Splits Calendar. A stock split occurs when a company issues additional shares to existing investors, increasing the total share count without changing its overall market value. The result is a lower price per share, making the stock appear more affordable to everyday investors. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter On the flip side, a reverse stock split shrinks the share count by combining existing shares, driving the price per share higher while keeping the total valuation intact. Companies often use this move to stay in compliance with stock exchange rules, particularly when their share price is hovering near delisting thresholds like Nasdaq's minimum requirement. Whether to attract investor attention or to meet listing standards, these maneuvers can offer important clues about a company's current priorities and future strategy. Let's take a look at the upcoming stock splits for the week. Jianzhi Education Technology Group (JZ) – Beijing‑based Jianzhi is a digital education provider offering online learning platforms and professional development content to higher education institutions and individuals across China. On June 12, the company announced an upcoming 1‑for‑10 reverse ADS split to boost its ADS trading price and maintain Nasdaq listing compliance. The split is scheduled to be effective at the start of trading on June 16. GlycoMimetics (GLYC) – U.S.-based GlycoMimetics is a clinical-stage biotech company developing treatments for sickle cell disease and cancer by targeting cell adhesion. On June 5, the company announced a 1-for-100 reverse stock split to support its planned merger with Crescent Biopharma. The split will take effect June 16, with shares trading under the new ticker CBIO as the combined company moves forward. Neo-Concept International Group Holdings (NCI) – Neo-Concept is a Hong Kong-headquartered apparel supplier and importer serving global e-commerce platforms. Following shareholder approval at its May 9 meeting, the company is rolling out a 1-for-5 reverse share consolidation. The adjustment takes place June 16. Shuttle Pharmaceuticals (SHPH) – Shuttle Pharmaceuticals is advancing a pipeline of radiation-sensitizing drugs aimed at improving cancer outcomes. On June 12, it unveiled a 1-for-25 reverse stock split to bring its share price back in line with Nasdaq's minimum bid requirement. The split becomes effective June 16, with SHPH shares trading on a split-adjusted basis that morning. Jeffs' Brands (JFBR) – Jeffs' Brands operates data-driven e-commerce brands across major online marketplaces, including Amazon. After securing shareholder approval, the company announced on June 12 a 1-for-17 reverse stock split aimed at maintaining its Nasdaq listing. The change goes live June 16. Security Matters (SMX) – Dublin-based Security Matters offers advanced digital tracking and authentication solutions for supply chains and product integrity. The company is implementing a 4.1-for-1 reverse stock split, which was approved earlier this spring and formally announced on June 12. The split is scheduled to take effect June 16. Glucotrack (GCTK) – Glucotrack is a med-tech innovator developing non-invasive glucose monitoring solutions for diabetes management. To meet Nasdaq compliance standards, the company announced a 1-for-60 reverse stock split on June 12, following prior shareholder approval at its May 22 annual meeting. The split becomes effective June 16. Regencell Bioscience Holdings (RGC) – Hong Kong–based Regencell is on a mission to treat neurocognitive disorders like ADHD and autism using traditional Chinese medicine. On June 2, the company unveiled a 38-for-1 forward stock split to boost liquidity and attract retail interest. Shareholders of record as of June 12 received their additional shares on June 13, and RGC began trading on a split-adjusted basis on June 16. Sensei Biotherapeutics (SNSE) – Sensei is a clinical-stage biotech based in Boston, developing next-gen immunotherapies to take on cancer. On June 13, the company announced a 1-for-20 reverse stock split in an effort to meet Nasdaq's minimum price threshold and maintain its listing. The split takes effect on June 16, with adjusted trading kicking off on June 17. RAPT Therapeutics (RAPT) – RAPT is advancing innovative therapies targeting inflammatory and autoimmune diseases. On June 13, the company rolled out a 1-for-8 reverse stock split aimed at reshaping its capital structure. The move becomes official on June 16, with split-adjusted shares starting to trade on June 17. FibroGen (FGEN) – FibroGen is a biotech company focused on fibrosis and other serious diseases. On June 12, it announced a 1-for-25 reverse stock split designed to help the stock climb back above the Nasdaq's minimum bid requirement. The split becomes effective on June 16, with trading on a split-adjusted basis beginning June 17. Interactive Brokers Group (IBKR) – A powerhouse in online trading, Interactive Brokers is known for serving active investors with low-cost, high-tech tools. On April 15, the company declared a 4-for-1 forward stock split to make shares more accessible to a broader investor base. Shareholders of record on June 16 received the extra shares on June 17, and IBKR stock began trading at the new price on June 18. TipRanks Stock Splits Calendar.
Yahoo
3 hours ago
- Yahoo
Veteran analyst sends surprising message on stocks, bonds, and gold
Veteran analyst sends surprising message on stocks, bonds, and gold originally appeared on TheStreet. The stock market rally has been impressive. Since President Donald Trump paused most reciprocal tariffs on April 9, only days after announcing them, stocks have soared. The S&P 500 has gained about 20%, while the tech-stock heavy Nasdaq Composite is up 27%. Those returns in such a short span significantly outpace the average 10% annual return for stocks since 1928. Stocks haven't been the only winner. Gold has also notched impressive returns this year. The yellow metal has rallied 30% in 2025 as investors have sought to insulate risk amid growing economic concerns surrounding debt and the impact of tariffs on one big disappointment this year: Treasury bonds. They've tumbled, sending bond yields soaring, as global investors have soured on financing America's insatiable appetite for spending. The market action has captured the attention of many, including veteran commodities and futures analyst Carley Garner. Garner has been professionally navigating these markets for 20 years, and her track record includes accurately predicting the stock rally in 2023 and last year's decline in oil prices. Garner updated her outlook on stocks, gold, and bonds, and her takeaway may surprise you. Stocks' rally since the lows in early April likely surprised many, given significant economic risks remain. While inflation has retreated below 3% from over 8% in 2022, price increases over the past years have cash-strapped consumers, causing them to shift spending from discretionary purchases to problem has been compounded by an uptick in unemployment, which has increased to 4.2% from 3.4% in 2023, partly due to higher interest rates designed to crimp inflation. According to Challenger, Gray, & Christmas, U.S. companies have laid off 696,309 workers this year through May, up 80% from one year ago. The situation isn't likely to get much better for workers. While Trump paused many reciprocal tariffs in April, key tariffs remain, including a 25% tariff on Canada and Mexico and autos, a 10% tariff on all imports, and 30% tariff on China (total tariffs on China, including those put in place during President Trump's first term exceed 50%). The remaining tariffs, and potential for more after the 90-day pause expires, could fuel inflation later this year, particularly in retail, which sources everything from clothing to electronics from overseas. The risk of inflation alongside job losses suggests America could go headlong into a period of stagflation or recession. Despite those risks, the S&P 500 and Nasdaq Composite have notched remarkable gains. Investors who quickly sold amid tariff announcements earlier this year have been left behind, and as a result, they're buying every dip to regain their exposure. One major exception? Warren Buffett. The Oracle of Omaha has increased Berkshire Hathaway's cash position, choosing to collect guaranteed fixed income from T-bills rather than leap back into the stock market amid the uncertainty. Exiting the first quarter, Warren Buffett's cash stockpile eclipsed $347 billion, a record, and more than double the levels exiting 2023. The rallies in stocks and gold may continue, but like Buffett, Carley Garner doesn't see the risk-to-reward as overly compelling in stocks. She's also become bearish on gold relative to bonds, given that gold has moved significantly higher and, unlike bonds, doesn't pay dividends. "While I believe the S&P 500 can easily reach 6300 to 6400, the downside risk might be outsized relative to the potential reward," wrote Garner on TheStreet Pro. "Since 1928, the S&P 500 has returned an average annual rate of 10%; however, in recent years, the average return has been abnormally high, at approximately 14%. There is a good chance that, like the dot-com era, we have pulled forward gains and could be on the verge of a 'returnless' market in the coming years." Garner points to a key measure favored by Warren Buffett regarding stock market valuation as evidence that stocks are over their skis. More Experts: Fed official sends strong message about interest-rate cuts Billionaire fund manager sends surprising message on trade deficit Hedge-fund manager sees U.S. becoming Greece "The Warren Buffett Indicator measures the total stock market value vs. the GDP," wrote Garner. "Since 1950, the stock market has only been this overstretched a few other times. Not surprisingly, the dot-com bubble was one of those times. Historically, this indicator has not been the time to hit the gas on risk assets. It has been the opposite." The arguable overvaluation of stocks could mean the risk of a reckoning is high enough to concentrate on other assets. However, gold may not be the best bet, given it's already made a big move higher. Instead, it's Treasury bonds that Garner believes offer the best chance for upside. "There is only one [of these assets] near a two-decade low in valuation: Treasuries," writes Garner. "Except for some forms of real estate, it is the only asset that yields an attractive income stream. Lastly, Treasuries are the least risky asset class in the world but the market is treating the securities as anything but." Garner points out that people were flocking to own bonds with paltry yields only five years ago. Now, they're shunning yields near 4.5%. Many are hesitant to own bonds despite the high yields, fearing that bonds will continue to drop, sending yields even higher, as the U.S. debt load rises. While it's true that lower bond values could mean short-term losses, Garner views the risk of a U.S. default as unlikely, suggesting that those holding Treasuries to maturity will be fine, and pocket healthy income along the way. "Historically, there have been two other instances in history when stocks were as overvalued as they are now relative to bonds. Or, alternatively, bonds were this undervalued relative to stocks," wrote Garner. "Such opportunities have only arisen once every two decades, and they have proven to be significant inflection points in both stocks (the beginning of prolonged underperformance) and bonds (the start of a period of capital gains to enhance interest earned). This metric has been similarly favoring bonds since the initial collapse in 2023, so instant satisfaction shouldn't be expected, but patience will likely pay off."Veteran analyst sends surprising message on stocks, bonds, and gold first appeared on TheStreet on Jun 15, 2025 This story was originally reported by TheStreet on Jun 15, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
